Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis, Remittent Progressive
Multiple Sclerosis, Primary Progressive
Secondary Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis

Interventions: Drug: BIIB041 (fampridine)
Drug: Placebo

First Posted Date: 2013-08-06

Last Posted Date: 2017-03-21

Lead Sponsor: Biogen

Target Recruit Count: 101

Registration Number: NCT01917019

Locations: 🇯🇵
Research Site, Yachiyo-shi, Japan

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: bismuth subsalicylate (Pepto-Bismol®)
Drug: matching placebo (bismuth subsalicylate)
Drug: dimethyl fumarate (DMF)

First Posted Date: 2013-08-05

Last Posted Date: 2014-03-03

Lead Sponsor: Biogen

Target Recruit Count: 175

Registration Number: NCT01915901

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Completed

Conditions: Multiple Sclerosis
Exposure During Pregnancy

Interventions: Drug: Peginterferon beta-1a
Drug: Dimethyl fumarate

First Posted Date: 2013-07-30

Last Posted Date: 2022-06-21

Lead Sponsor: Biogen

Target Recruit Count: 408

Registration Number: NCT01911767

Locations: 🇬🇧
Research Site, Salford, Greater Manchester, United Kingdom

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

Completed

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Drug: dimethyl fumarate

First Posted Date: 2013-07-19

Last Posted Date: 2016-07-25

Lead Sponsor: Biogen

Target Recruit Count: 333

Registration Number: NCT01903291

Locations: 🇺🇸
Research Site, Neenah, Wisconsin, United States

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Phase 1

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Biological: Natalizumab

First Posted Date: 2013-06-24

Last Posted Date: 2016-06-23

Lead Sponsor: Biogen

Target Recruit Count: 13

Registration Number: NCT01884935

Locations: 🇮🇹
Research Site, Rome, Italy

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

Phase 2

Completed

Conditions: Painful Lumbar Radiculopathy
Sciatica
Radiculopathy

Interventions: Drug: BG00010
Drug: Placebo

First Posted Date: 2013-06-10

Last Posted Date: 2015-09-10

Lead Sponsor: Biogen

Target Recruit Count: 183

Registration Number: NCT01873404

Locations: 🇺🇸
Research Site, Salt Lake City, Utah, United States

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

Phase 4

Completed

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Drug: BG00012 (DMF)

First Posted Date: 2013-06-10

Last Posted Date: 2017-03-21

Lead Sponsor: Biogen

Target Recruit Count: 237

Registration Number: NCT01873417

Locations: 🇺🇸
Research Site, Milwaukee, Wisconsin, United States

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: BIIB033
Other: Placebo
Drug: Avonex

First Posted Date: 2013-05-29

Last Posted Date: 2017-05-03

Lead Sponsor: Biogen

Target Recruit Count: 419

Registration Number: NCT01864148

Locations: 🇺🇸
OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, United States
🇨🇦
Research Site, Montreal, Quebec, Canada
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 65 locations

Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)

Phase 1

Completed

Conditions: Healthy
Painful Lumbar Radiculopathy

Interventions: Drug: Placebo IV
Biological: BG00010 SC
Biological: BG00010 IV
Drug: Placebo SC

First Posted Date: 2013-04-29

Last Posted Date: 2015-02-09

Lead Sponsor: Biogen

Target Recruit Count: 54

Registration Number: NCT01842126

Locations: 🇳🇱
Center for Human Drug Research, Leiden, Netherlands

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

Phase 2

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: nusinersen

First Posted Date: 2013-04-25

Last Posted Date: 2021-02-17

Lead Sponsor: Biogen

Target Recruit Count: 21

Registration Number: NCT01839656

Locations: 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇨🇦
The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 1 locations

Home Terms & Conditions Privacy Policy